MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

Search

Novo Nordisk A-S

Atvērts

SektorsVeselības aprūpe

59.6 0.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

59.04

Max

60.11

Galvenie mērījumi

By Trading Economics

Ienākumi

-2.5B

27B

Pārdošana

-1.2B

77B

P/E

Sektora vidējais

15.217

37.257

Dividenžu ienesīgums

2.9

Peļņas marža

34.484

Darbinieki

78,387

EBITDA

-2.5B

44B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+0.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.90%

2.94%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

53B

269B

Iepriekšējā atvēršanas cena

59.13

Iepriekšējā slēgšanas cena

59.6

Ziņu noskaņojums

By Acuity

16%

84%

26 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Novo Nordisk A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. okt. 08:54 UTC

Galvenie tirgus virzītāji

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

2025. g. 18. aug. 13:52 UTC

Galvenie tirgus virzītāji

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

2025. g. 18. aug. 09:23 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025. g. 18. aug. 09:23 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025. g. 6. aug. 06:52 UTC

Peļņas

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

2025. g. 6. aug. 06:21 UTC

Peļņas

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2025. g. 7. okt. 09:15 UTC

Tirgus saruna

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

2025. g. 1. okt. 09:05 UTC

Karstas akcijas

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

2025. g. 29. sept. 12:04 UTC

Tirgus saruna

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

2025. g. 22. sept. 13:43 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

2025. g. 18. sept. 12:30 UTC

Tirgus saruna

Correction to Novo Nordisk Market Talk

2025. g. 18. sept. 12:00 UTC

Tirgus saruna

Novo Nordisk's Prospects Could Turn Around -- Market Talk

2025. g. 18. sept. 08:55 UTC

Karstas akcijas

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

2025. g. 11. sept. 10:59 UTC

Tirgus saruna

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

2025. g. 10. sept. 13:24 UTC

Peļņas

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

2025. g. 10. sept. 09:16 UTC

Karstas akcijas

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2025. g. 2. sept. 09:14 UTC

Karstas akcijas

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

2025. g. 21. aug. 08:49 UTC

Peļņas
Karstas akcijas

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

2025. g. 18. aug. 09:23 UTC

Karstas akcijas

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

2025. g. 8. aug. 05:32 UTC

Tirgus saruna

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

2025. g. 7. aug. 11:32 UTC

Peļņas

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 11:03 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 10:41 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

2025. g. 6. aug. 20:34 UTC

Peļņas

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

2025. g. 6. aug. 08:45 UTC

Peļņas

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

2025. g. 6. aug. 07:19 UTC

Tirgus saruna
Peļņas

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

2025. g. 6. aug. 05:50 UTC

Peļņas

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

2025. g. 6. aug. 05:48 UTC

Peļņas

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

2025. g. 6. aug. 05:46 UTC

Peļņas

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

2025. g. 6. aug. 05:38 UTC

Peļņas

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S Prognoze

Cenas mērķis

By TipRanks

0.86% augšup

Prognoze 12 mēnešiem

Vidējais 59.53 USD  0.86%

Augstākais 70 USD

Zemākais 47 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

2

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

62.63 / 69.23Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

26 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat